Bradyco Inc. purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 12,567 shares of the company's stock, valued at approximately $1,817,000. Johnson & Johnson accounts for 1.3% of Bradyco Inc.'s portfolio, making the stock its 16th biggest holding.
Several other large investors have also recently added to or reduced their stakes in the company. Novus Advisors LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $822,000. Edgestream Partners L.P. boosted its position in shares of Johnson & Johnson by 180.9% during the 4th quarter. Edgestream Partners L.P. now owns 56,595 shares of the company's stock worth $8,185,000 after purchasing an additional 36,444 shares in the last quarter. BBR Partners LLC grew its stake in shares of Johnson & Johnson by 3.2% during the 4th quarter. BBR Partners LLC now owns 28,355 shares of the company's stock worth $4,101,000 after purchasing an additional 881 shares during the period. West Family Investments Inc. increased its holdings in shares of Johnson & Johnson by 11.1% in the 4th quarter. West Family Investments Inc. now owns 10,795 shares of the company's stock valued at $1,561,000 after purchasing an additional 1,076 shares in the last quarter. Finally, Destination Wealth Management lifted its stake in shares of Johnson & Johnson by 1.2% in the fourth quarter. Destination Wealth Management now owns 271,859 shares of the company's stock valued at $39,316,000 after purchasing an additional 3,322 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
JNJ has been the topic of several recent analyst reports. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 23rd. Raymond James dropped their price objective on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research note on Thursday, January 23rd. Leerink Partners reduced their price objective on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Guggenheim upped their target price on Johnson & Johnson from $162.00 to $166.00 and gave the company a "neutral" rating in a report on Monday, February 3rd. Finally, Bank of America lifted their price target on Johnson & Johnson from $159.00 to $171.00 and gave the stock a "neutral" rating in a research note on Wednesday. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $171.33.
Read Our Latest Stock Analysis on Johnson & Johnson
Insider Buying and Selling
In other news, Director Mark A. Weinberger bought 1,000 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company's stock, valued at $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.
Johnson & Johnson Trading Up 0.6 %
NYSE JNJ traded up $0.98 during mid-day trading on Friday, reaching $166.81. 9,636,645 shares of the stock were exchanged, compared to its average volume of 7,032,060. The business's fifty day simple moving average is $152.95 and its 200 day simple moving average is $156.28. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a market capitalization of $401.61 billion, a PE ratio of 25.08, a PEG ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the previous year, the business earned $2.29 earnings per share. The business's revenue for the quarter was up 5.3% on a year-over-year basis. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were issued a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 2.97%. Johnson & Johnson's payout ratio is currently 74.59%.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
